High-density lipoprotein cholesterol as a risk factor and target of therapy after acute coronary syndrome

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Interventional Cardiology

Background:

• Acute coronary syndrome (ACS) remains a leading cause of morbidity and mortality despite current treatments.
• Low high-density lipoprotein (HDL) cholesterol levels are prevalent in ACS patients and indicate a higher risk of future cardiovascular events, even with statin therapy.
• HDL cholesterol is implicated in beneficial vascular effects, including plaque stabilization and improved endothelial function.

Purpose of the Study:

• To explore the potential benefits of high-density lipoprotein (HDL) cholesterol in patients following acute coronary syndrome (ACS).
• To summarize evidence suggesting HDL cholesterol's protective roles against post-ACS complications.
• To highlight ongoing clinical trials evaluating HDL-raising strategies for ACS risk reduction.

Main Methods:

• Review of existing clinical and experimental data on HDL cholesterol and ACS.
• Analysis of HDL's proposed mechanisms of action in cardiovascular disease.
• Identification of ongoing clinical trials assessing HDL-raising therapies.

Main Results:

• Low HDL cholesterol is a significant predictor of adverse outcomes in ACS patients.
• Experimental and clinical data suggest HDL cholesterol possesses atheroprotective and anti-inflammatory properties.
• HDL cholesterol may mitigate endothelial dysfunction, thrombosis, inflammation, oxidative stress, and ischemia-reperfusion injury.

Conclusions:

• HDL cholesterol plays a potentially crucial role in managing patients with acute coronary syndrome (ACS).
• Strategies aimed at increasing HDL cholesterol levels are under investigation as a novel therapeutic approach for ACS.
• Further clinical trials are necessary to confirm the efficacy of HDL-raising therapies in reducing cardiovascular events post-ACS.